SCHEMBL7877993

SCHEMBL7877993

CN(C(=N)N)C(=O)c1cc2ccc(OCc3ccc(CN)cc3)cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MAOB P27338 5/20 0.43
ACHE P22303 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
SRD5A2 P31213 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CFD P00746 1/20 0.41
F2 P00734 3/20 0.40
MAOA P21397 2/20 0.39
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7878027 0.93 MEN1 (0.48) FLT3MEN1KMT2ARXFP1MAOB
SCHEMBL7877731 0.92 MEN1 (0.48) FLT3MEN1KMT2ARXFP1MAOB
Hydrochloric Acid SCHEMBL7877487 0.90 FLT3 (0.58) FLT3MEN1KMT2ARXFP1MAOB
SCHEMBL7881184 0.89 KMT2A (0.47) FLT3MEN1KMT2ARXFP1PDGFRB
SCHEMBL7873705 0.89 MEN1 (0.46) FLT3MEN1KMT2ARXFP1MAOB
SCHEMBL7877889 0.86 MEN1 (0.50) FLT3MEN1KMT2ARXFP1MAOB
SCHEMBL7884905 0.86 MEN1 (0.47) FLT3MEN1KMT2ARXFP1MAOB
SCHEMBL7881580 0.85 MEN1 (0.41) FLT3MEN1KMT2ARXFP1PDGFRB
SCHEMBL7880078 0.85 MEN1 (0.41) FLT3MEN1KMT2ARXFP1PDGFRB
SCHEMBL7879727 0.85 FLT3 (0.48) FLT3MEN1KMT2ARXFP1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed